PIK3CA and breast carcinoma: Several tissue-agnostic clinical trials are investigating PI3K inhibitors to expand their therapeutic applications beyond breast cancer: NCT04439175, NCT05490771, NCT05307705, NCT06132932, NCT01449370, NCT01449370, and NCT06417391.